January 25, 2021 -- Novavax has finalized an agreement with the Canadian government to supply up to 76 million doses of NVX-CoV2373, a recombinant protein-based COVID-19 vaccine.
Canada has already committed to purchase 52 million doses of the vaccine and has executed its option for up to an additional 24 million doses.
NVX-CoV2373 is currently in phase III clinical development for the prevention of COVID-19. The company expects to supply NVX-CoV2373 to Canada beginning as early as the second quarter of 2021, following authorization by Canada's regulatory agency. Novavax also expects to announce initial phase III efficacy results as early as the first quarter of 2021.